These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 24165444)

  • 1. Cost-effectiveness of test phase implantation strategies for InterStim® sacral neuromodulation.
    Kantartzis KL; Shepherd JP
    Female Pelvic Med Reconstr Surg; 2013; 19(6):322-7. PubMed ID: 24165444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
    Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
    J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain.
    Brosa M; Muñoz-Duyos A; Navarro-Luna A; Rodriguez JM; Serrano D; Gisbert R; Dziekan K; Segú JL
    Curr Med Res Opin; 2008 Mar; 24(3):907-18. PubMed ID: 18279582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW; Bercik RS; Werner EF; Thung SF
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
    Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
    Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
    Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
    J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
    Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
    Theriou C; Fielden CA; Kitterick PT
    Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness.
    Indinnimeo M; Ratto C; Moschella CM; Fiore A; Brosa M; Giardina S
    Dis Colon Rectum; 2010 Dec; 53(12):1661-9. PubMed ID: 21178862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.
    Nilsson FO; Linnér L; Samuelsson E; Milsom I
    BJU Int; 2012 Jul; 110(2):240-6. PubMed ID: 22093912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
    Stylopoulos N; Gazelle GS; Rattner DW
    Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain.
    Kumar K; Rizvi S; Bishop S
    Clin J Pain; 2013 Feb; 29(2):138-45. PubMed ID: 22699140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.